Open AccessSafety and efficacy of single‐agent docetaxel ( T axotere) administered weekly in non‐small cell lung carcinoma patients in K orea: An observational study
Author(s) -
Lim Sun Min,
Park Byeong Bae,
Park KeunChil,
Kim HoonKyo,
Lee Jong Seok,
Bae Sung Hwa,
Lee SeungSei,
Kang JinHyoung,
Park SeHoon,
Lee GyeongWon,
Lee HyoRac,
Seo Jae Hong,
Kim Yong Tae,
Yang Sung Hyun,
Kim JooHang
Publication year - 2016
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12315
Subject(s) - medicine , docetaxel , tolerability , common terminology criteria for adverse events , adverse effect , neutropenia , lung cancer , regimen , oncology , gastroenterology , cancer , toxicity
Background To investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non‐small cell lung cancer ( NSCLC ) patients in K orea. Methods This prospective observational study included K orean advanced NSCLC patients with E astern C ooperative O ncology G roup performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. Efficacy measurements included tumor response rate, overall survival ( OS ), progression‐free survival, and one‐year survival rate. Safety was analyzed through recorded incidences of adverse events ( AEs ), serious adverse events ( SAEs ), deaths, and other related safety parameters, along with their toxicity grades. Results: Of 274 patients analyzed, one patient achieved a complete response and 42 partial responses; thus, the overall response rate was 15.7%. The OS rate at baseline and at one‐year follow‐up was 38.3% and 33.8%, respectively. AEs were reported in 229 (83.6%) patients. The most frequently reported hematologic AE of grade ≥3 was a decrease in neutrophils, with 6.6% of the patients developing neutropenia. In non‐hematologic AEs of grade ≥3, the most common were infection with unknown absolute neutrophil count and death not associated with C ommon T erminology C riteria for A dverse E vents ( CTCAE ) (4.7% each). The most common SAE reported was death, not associated with CTCAE (7.3%). Conclusions In K orean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced NSCLC .